Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain. - Barron's
1. Novo Nordisk's CagriSema weight-loss treatment trial results underperformed expectations. 2. CagriSema showed only 15.7% weight loss compared to the expected 25%. 3. Novo shares dropped 9%, while LLY shares fell 3.5%. 4. Eli Lilly's Zepbound shows better efficacy against Novo's Wegovy. 5. Regulatory approval for CagriSema is expected in Q1 2026.